Phathom Pharmaceuticals Inc (NAS:PHAT)

$ 10.05 -0.28 (-2.71%) Market Cap: 588.28 Mil Enterprise Value: 432.49 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 31/100

Q4 2023 Phathom Pharmaceuticals Inc Earnings Call Transcript
Mar 07, 2024

$9.09 (-6.58%)

Earnings
Phathom Pharmaceuticals Inc to Discuss The FDA Approval Transcript
Nov 02, 2023
Phathom Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Phathom Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 18, 2023
Phathom Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 12, 2022
Phathom Pharmaceuticals Inc Conference call on the PHALCON-EE Trial Results Transcript
Oct 18, 2021
Phathom Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 14, 2021
Phathom Pharmaceuticals Inc at Jefferies Healthcare Conference (Virtual) Transcript
Jun 01, 2021
Phathom Pharmaceuticals Inc Annual Shareholders Meeting Transcript
May 21, 2021
Phathom Pharmaceuticals Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 13, 2021
Phathom Pharmaceuticals Inc Phase 3 PHALCON-HP Results Corporate Call Transcript
Apr 29, 2021
Phathom Pharmaceuticals Inc Corporate Analyst Meeting Transcript
Dec 14, 2020
Phathom Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 15, 2020
Phathom Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 11, 2020
Phathom Pharmaceuticals Inc Annual Shareholders Meeting Transcript
May 21, 2020

Phathom Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript

Jun 14, 2023 / 03:00PM GMT

Release Date Price: $12.77 (-2.82%)

Transcript

Paul Choi;Terrie J. Curran

Goldman Sachs Group, Inc., Research Division - Equity Analyst;Phathom Pharmaceuticals, Inc. - President, CEO

Okay. Good morning, everyone. I'm Paul Choi. I cover the small and mid-cap biotechnology sector here at Goldman Sachs. Before we begin (inaudible) disclosures regarding (inaudible) disclosures are available that allow us (inaudible).

However, they are available on our research portal for your information. Goldman Sachs only undertakes us under the assumption that any third-party speaker here today will not provide any confidential or material nonpublic information.

Additionally, the views expressed by third parties do not necessarily reflect those of Goldman Sachs. And with that, we'll continue. It's my pleasure to welcome Phathom Pharmaceuticals here. We're joined by the senior management team. And starting on my left is Martin. Then, to my immediate right, at the far end, sorry, we have Azmi, Molly and Terrie.

What we'll do is let Terrie kick it off with some opening remarks, and then we'll get into Q&A.

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.